International Association for the Study of Lung Cancer

06/18/2026

🧬 Circulating tumor DNA is associated with disease recurrence in those with early stage NSCLC. Here, Feng et al. demonstrate the clinical feasibility of using plasma ctDNA to inform treatment decisions for those with stage I NSCLC. Read more: https://bit.ly/4xqxN9q

06/18/2026

recap: Dr. Jonathan W. Goldman shares how findings from the LIBRETTO-432 trial support adjuvant selpercatinib as a new standard of care for patients with early-stage RET fusion-positive NSCLC.

🔗 Read his insights now in ILCN:

Dr. Jonathan W. Goldman said that findings from the LIBRETTO-432 trial support adjuvant selpercatinib as a new standard of care for patients with early-stage RET fusion-positive NSCLC.

06/17/2026

🎉 Congratulations to Agbonvihele Gregrey Oko-Oboh on being selected as a recipient of the IASLC African Impact Grant!

Through the IASLC African Impact Grant, we are proud to support innovative research that addresses critical challenges in thoracic oncology across Africa and helps improve outcomes for patients.

Please join us in congratulating Agbonvihele on this well-deserved achievement and wishing him success with this important work.

06/16/2026

Hear from Co-Chair Ferdinando Cerciello on what makes the IASLC Hot Topic Conference 2026 a unique experience.

Designed as a small, highly interactive meeting, Hot Topic brings together leading experts and attendees for meaningful discussion, direct access to faculty, and valuable peer-to-peer exchange. Join us in Dublin for focused, high-impact science on resistance to immunotherapy in a setting that encourages collaboration, conversation, and connection.

Register now: https://bit.ly/4oxlXXb

06/15/2026

In the newest JTO Insights episode, Drs. Alex Adjei and Tom John are joined by Drs. Natasha B. Leighl and Gabriella Sozzi to discuss research on tumor-informed plasma ctDNA in high-risk stage I NSCLC and the potential role of blood-based testing alongside low-dose CT screening.

🔬 From risk assessment to screening accuracy, emerging biomarkers are helping shape the future of lung cancer care.

In the newest JTO Insights episode, Drs. Alex Adjei and Tom John are joined by Drs. Natasha B. Leighl and Gabriella Sozzi to discuss research on tumor-informed plasma ctDNA in high-risk stage I NSCLC and the potential role of blood-based testing alongside low-dose CT screening.

Listen here: https://bit.ly/4ofCEWS

International Association for the Study of Lung Cancer

06/14/2026

🫁 Drs. Mino-Kenudson and Berezowska suggest that a standardized two-tier grading system presents an important step toward harmonizing LUSC grading worldwide.

🔗 Learn more in ILCN:

Drs. Mari Mino-Kenudson and Sabina Berezowska suggest that a standardized two-tier grading system presents an important step toward harmonizing LUSC grading worldwide.

06/13/2026

🌏 What makes the IASLC World Conference on Lung Cancer the premier global meeting in thoracic oncology?

In this special episode of Lung Cancer Considered, hosts Drs. Stephen Liu and Narjust Florez are joined by Drs. Myung-Ju Ahn, Vincent Wentao Fang, Jiraporn Setakornnukul, and Yasushi Yatabe to preview , taking place September 12–15, 2026, in Seoul, Republic of Korea.

The discussion covers key deadlines, multidisciplinary program highlights, and what attendees can expect from one of the world's leading gatherings focused on lung cancer research, education, and patient care.

🎧 Listen now: https://bit.ly/49R0gLG

06/12/2026

⏰ Today is the last day to save on registration for the 2026 World Conference on Lung Cancer!
Register by the end of today to receive Early Bird pricing and save up to $500. IASLC Members can save even more, with total savings of up to $750.

Don't miss your opportunity to join colleagues from around the world for four days of cutting-edge science, multidisciplinary collaboration, and meaningful connections with the global thoracic oncology community.

Register today: https://bit.ly/wclcreg26

06/12/2026

In this study, Zanghì et al. used peripheral blood mononuclear cell profiling to personalize LDCT screening intervals to try to combat the rate of false positives and increase accuracy.
Read the full article: https://bit.ly/3OrV5tR


Fondazione IRCCS Istituto Nazionale dei Tumori

06/11/2026

🌍 Help shape the future of the World Conference on Lung Cancer.

IASLC is seeking visionary leaders to serve as Co-Chairs for the 2028 World Conference on Lung Cancer (WCLC) in Copenhagen, Denmark. This is an opportunity to help guide the scientific direction of the world’s largest conference dedicated to thoracic oncology and work alongside a global, multidisciplinary community committed to advancing lung cancer research and care.

If you are passionate about education, collaboration, and innovation in thoracic oncology, we encourage you to learn more and apply.

📅 Applications are open.

Learn more and apply: https://bit.ly/4oe7a3i